Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Gan & Lee Pharmaceuticals Signs Out‑Licensing Deal With Menarini on Bonfaglutide, a Twice‑Monthly GLP‑1 RA, Worth Up to EUR 726 Million Across 39 European Markets

Fineline Cube Aug 11, 2026
Company Deals

Jazz Pharmaceuticals to Acquire Actio Biosciences for Up to USD 1.32 Billion, Gaining First‑in‑Class KCNT1 Ion Channel Inhibitor ABS‑1230 for Ultra‑Rare Epilepsy

Fineline Cube Aug 11, 2026
Company Deals

Novo Nordisk Names AWS Preferred Cloud Provider and Strategic AI Partner to Accelerate Drug Discovery With Agentic AI

Fineline Cube Aug 11, 2026
Company Deals

Xbiome and BioMap Sign Strategic Cooperation Agreement to Advance AI‑Powered Microbiome Drug and Probiotic Product R&D

Fineline Cube Aug 11, 2026
Company Deals

BeOne Medicines and Revolution Medicines Announce Clinical Collaboration and Regional Licensing Deal on RAS(ON) Inhibitors Across Select Asian Markets

Fineline Cube Aug 11, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

Zhifei Biological Submits Clinical Trial Application in China for Nasal Spray Recombinant RSV Vaccine Based on Chimpanzee Adenovirus Vector

Fineline Cube Aug 11, 2026
Company Drug

Keymed Biosciences’ Bispecific Antibody CM512 Achieves All Endpoints in Phase 2 Trial for Chronic Rhinosinusitis With Nasal Polyps

Fineline Cube Aug 11, 2026
Company Drug

Janssen Presents Real-World Data on Tremfya’s Efficacy in Treatment-Resistant Psoriatic Arthritis

Fineline Cube Nov 9, 2023

Johnson & Johnson’s (J&J; NYSE: JNJ) pharmaceutical unit, Janssen, has presented real-world efficacy data for...

Company Deals Hospital

Zhejiang Boner Medical Secures Over RMB 800 Million in Pre-IPO Financing for Strategic Expansion

Fineline Cube Nov 9, 2023

Zhejiang Boner Medical Investment Management Co., Ltd., known as Bang-er Orthopedics, a leading hospital investment...

Company Drug

ImmuneOnco Biopharmaceuticals’ Timdarpacept (IMM01) Earns Orphan Drug Designation for CMML

Fineline Cube Nov 9, 2023

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced that it has received orphan drug...

Company Medical Device

Lifetech Scientific Corporation Receives NMPA Approval for Peripheral Thrombus Suction Catheter

Fineline Cube Nov 9, 2023

Lifetech Scientific Corporation (HKG: 1302), a China-based medical device company, has announced that it has...

Company

Bayer’s Q3 2023 Financial Report: A Mixed Bag with Consumer Health Driving Growth

Fineline Cube Nov 9, 2023

Germany-based major Bayer (ETR: BAYN) published its financial report for the third quarter of 2023,...

Company

Viatris Inc. Reports Q3 2023 Global Net Sales Growth of 1% and Highlights from Earnings Call

Fineline Cube Nov 9, 2023

US-based generics giant Viatris Inc., (NASDAQ: VTRS) has released its financial results for the third...

Company Drug

Abbisko Therapeutics’ CD73 Inhibitor ABSK051 Clears for Phase I Clinical Trial in China

Fineline Cube Nov 9, 2023

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received approval...

Company Drug

US FDA Approves HutchMed and Takeda’s Fruzaqla for Metastatic Colorectal Cancer Treatment

Fineline Cube Nov 9, 2023

The US Food and Drug Administration (FDA) has granted approval to HutchMed (NASDAQ: HCM) and...

Company Deals

Suzhou Porton Biologics Partners with BioMap to Enhance AAV Vector Design in Gene Therapy

Fineline Cube Nov 9, 2023

Suzhou Porton Biologics Ltd, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into...

Company Deals

CIIE 2023: Danaher, Boehringer-Ingelheim, Merck, J&J, BeiGene, and Fosun Pharma Announce China Partnerships

Fineline Cube Nov 9, 2023

The 6th China International Import Expo (CIIE) held in Shanghai this week has been a...

Company Deals

Zymeworks and BeiGene Terminate Licensing Agreement for ZW49 ADC

Fineline Cube Nov 8, 2023

Zymeworks Inc. (NASDAQ: ZYME), a Canada-based biotech company, has announced in its Q3 financial report...

Company Deals

Worg Pharmaceuticals Expands into Spain with Acquisition of Diater for EUR 150 Million

Fineline Cube Nov 8, 2023

Worg Pharmaceuticals, a Hangzhou-based developer of allergic drugs, has formally entered the Spanish market by...

Company Drug

Janssen’s Nipocalimab Shows Promising Results in Phase II Rheumatoid Arthritis Trial

Fineline Cube Nov 8, 2023

The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has announced the results of...

Company

Gilead Reports Q3 2023 Financials with 1% YOY Revenue Increase and Updates 2023 Outlook

Fineline Cube Nov 8, 2023

Gilead (NASDAQ: GILD) has released its financial results for the third quarter of 2023, showing...

Company Deals

AstraZeneca Expands China Presence with Over 30 Agreements at CIIE

Fineline Cube Nov 8, 2023

At the 6th China International Import Expo (CIIE) in Shanghai, UK-based pharmaceutical giant AstraZeneca plc...

Company

Moderna Initiates Construction of First China-Based Pharmaceutical Plant in Shanghai

Fineline Cube Nov 8, 2023

S-based mRNA specialist, Moderna (NASDAQ: MRNA), has commenced construction on its inaugural pharmaceutical facility in...

Company Deals

Senti Biosciences and Celest Therapeutics Partner on CAR-NK Cell Therapy Clinical Trial in China

Fineline Cube Nov 8, 2023

Senti Biosciences Inc., (NASDAQ: SNTI), a San Francisco-based biotech company, has announced a strategic collaboration...

Company Deals

Eisai Partners with Shanghai Pharmaceuticals for Alzheimer’s Drug Leqembi in China

Fineline Cube Nov 8, 2023

Eisai (TYO: 4523), a Japan-headquartered pharmaceutical company, has entered into a significant partnership with Shanghai...

Company Deals

Bayer and Shanghai Pharmaceuticals Launch Co.Lab to Incubate Life Sciences Innovation in China

Fineline Cube Nov 8, 2023

Bayer, the Germany-headquartered multinational pharmaceutical and life sciences company (ETR: BAYN), has entered into a...

Company Drug

Abbisko Therapeutics Receives FDA Approval for Phase I Study of FGFR4 Inhibitor ABSK012

Fineline Cube Nov 8, 2023

Shanghai-based biotech company Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received...

Posts pagination

1 … 487 488 489 … 706

Recent updates

  • Gan & Lee Pharmaceuticals Signs Out‑Licensing Deal With Menarini on Bonfaglutide, a Twice‑Monthly GLP‑1 RA, Worth Up to EUR 726 Million Across 39 European Markets
  • Zhifei Biological Submits Clinical Trial Application in China for Nasal Spray Recombinant RSV Vaccine Based on Chimpanzee Adenovirus Vector
  • Keymed Biosciences’ Bispecific Antibody CM512 Achieves All Endpoints in Phase 2 Trial for Chronic Rhinosinusitis With Nasal Polyps
  • Jazz Pharmaceuticals to Acquire Actio Biosciences for Up to USD 1.32 Billion, Gaining First‑in‑Class KCNT1 Ion Channel Inhibitor ABS‑1230 for Ultra‑Rare Epilepsy
  • CSPC Pharmaceutical Group’s Monkeypox mRNA Vaccine SYS6037 Receives FDA Approval to Conduct Clinical Trials in the US
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Gan & Lee Pharmaceuticals Signs Out‑Licensing Deal With Menarini on Bonfaglutide, a Twice‑Monthly GLP‑1 RA, Worth Up to EUR 726 Million Across 39 European Markets

Company Drug

Zhifei Biological Submits Clinical Trial Application in China for Nasal Spray Recombinant RSV Vaccine Based on Chimpanzee Adenovirus Vector

Company Drug

Keymed Biosciences’ Bispecific Antibody CM512 Achieves All Endpoints in Phase 2 Trial for Chronic Rhinosinusitis With Nasal Polyps

Company Deals

Jazz Pharmaceuticals to Acquire Actio Biosciences for Up to USD 1.32 Billion, Gaining First‑in‑Class KCNT1 Ion Channel Inhibitor ABS‑1230 for Ultra‑Rare Epilepsy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.